Fate Therapeutics Dividend
Dividend criteria checks 0/6
Fate Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$1.41 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues
Apr 23
Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%
Feb 16Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks
Jan 26Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry
Dec 19Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?
Sep 08Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price
Jun 07Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%
May 08Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?
Apr 17We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully
Jan 10Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation
Sep 22Fate Therapeutics: Yes For Speculators, No For Defensive Investors
Aug 30Needham initiates Fate coverage Therapeutics on potential of stem cell therapies
Jul 28Fate Therapeutics names Brian Powl as chief commercial officer
Jun 30Fate: Possible Speedy FDA Approval Process With RMAT Designation
Jun 03We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely
Jun 02Fate Therapeutics: Slowly Getting To An Attractive Position
Feb 21We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate
Feb 01Fate Therapeutics: Data Playing Catchup With Valuation
Dec 06Fate Therapeutics (NASDAQ:FATE) Is In A Good Position To Deliver On Growth Plans
Oct 16Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if FATE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FATE's dividend payments have been increasing.
Dividend Yield vs Market
| Fate Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (FATE) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (FATE) | 0% |
Notable Dividend: Unable to evaluate FATE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FATE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate FATE's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FATE has not reported any payouts.